TMIC-29. REPROGRAMMING BONE MARROW OF TUMOR-BEARING HOSTS FOR GLIOMA IMMUNOTHERAPY

ABSTRACT: Abstract

INTRODUCTION

We recently demonstrated that hematopoietic stem and progenitor cell (HSC) transfer during adoptive T cell immunotherapy (ACT) for malignant brain tumors facilitates extended survival and long-term cures. HSCs migrated to tumors and used T cell-released IFN-g to differentiate into dendritic cells (DCs). In those studies, we transferred syngeneic HSCs from naïve hosts that were not endemic to the tumor-bearing hosts, unlike the clinical paradigm of autologous transfers. In peripheral cancers, HSCs of tumor-bearing hosts (TB HSCs) possess considerable immunosuppressive potential.

OBJECTIVE

We therefore evaluated the immunologic function of HSCs from naïve and tumor-bearing hosts to determine if malignant gliomas affect the immune-potentiating function

SUBMITTER: Wildes T 

PROVIDER: S-EPMC6216412 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature